Stock comparison
Bruker
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BRKR
Bruker
Market cap
$6.96B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BRKR | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 33F | 65C | GMAB |
| Benjamin Graham | 44D | 64C | GMAB |
| Philip Fisher | 38D | 48D | GMAB |
| Peter Lynch | 30F | 25F | BRKR |
| Joel Greenblatt | 42D | 76B | GMAB |
| Charlie Munger | 40D | 68C | GMAB |
| Terry Smith | 38D | 71C | GMAB |
Side-by-side metrics
| Metric | BRKR | GMAB |
|---|---|---|
| Market cap | $6.96B | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | 34.2x | 12.0x |
| ROIC (TTM) | -2.92% | 43.78% |
| Gross margin | 45.56% | 93.88% |
| Net margin | -0.34% | 18.23% |
| Revenue CAGR 5y | 9.19% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.47% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BRKR leads on
- Revenue CAGR 5y9.19%vs -18.45%+150%
- P/E (TTM)-vs 6.2x+101%
- Dividend yield0.47%vs 0.0%+100%
GMAB leads on
- ROIC (TTM)43.78%vs -2.92%+107%
- Net margin18.23%vs -0.34%+102%
- Debt / Equity0.1xvs 0.7x+89%
- EV/EBIT12.0xvs 34.2x+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.